CureVac N.V. Aktie News

The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac's issued and outstanding shares, tendered prior to the expiration of the initial offering period The subsequent offering period has commenced and will expire at 12:01 a.m. Eastern Time on Thursday, December 18, 2025   MAINZ, Germany, December 3, 2025 – BioNTec...

CureVac N.V. ( CVAC ) Shareholder/Analyst Call November 25, 2025 8:00 AM EST Company Participants Mehdi Shahidi Marco Rau Thaminda Ramanayake - Chief Business Officer & Member of Executive Board Alexander Zehnder - CEO, MD & Member of Management Board Presentation Mehdi Shahidi Welcome, everyone, to this Extraordinary General Meeting of Shareholders of CureVac N.V.

TÜBINGEN, DE AND BOSTON, MA / ACCESS Newswire / November 25, 2025 / CureVac N.V. (Nasdaq:CVAC)(CureVac or the Company), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced the voting results of its Extraordinary General Meeting (EGM).

CureVac / NL0015436031

CureVac / NL0015436031

German Federal Cartel Office clearance obtained for the planned BioNTech - CureVac transaction announced on June 12, 2025, marking an important step toward the expected closing later this year Offer period for BioNTech's public exchange offer for all outstanding CureVac N.V. shares began on October 21, 2025, and is scheduled to expire on December 3, 2025 German litigation with Pfizer/BioNTech r...

CureVac / NL0015436031

Bei der geplanten Übernahme des Tübinger Impfstoff-Entwicklers Curevac NL0015436031 durch den Mainzer Konkurrenten Biontech US09075V1026 folgt der nächste Schritt.